Suppr超能文献

血小板与高密度脂蛋白比值(PHR)作为胃肠道癌症的预测生物标志物:来自美国国家健康与营养检查调查(NHANES)的证据。

Platelet-to-high-density lipoprotein ratio (PHR) as a predictive biomarker for gastrointestinal cancers: evidence from NHANES.

作者信息

Tong Yan, Lou Xiaojun

机构信息

Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.

Department of Gastroenterology, Jiaxing Hospital of Traditional Chinese Medicine, Jiaxing, Zhejiang, China.

出版信息

BMC Gastroenterol. 2025 Apr 27;25(1):302. doi: 10.1186/s12876-025-03860-9.

Abstract

BACKGROUND

Gastrointestinal (GI) cancers, including gastric, colorectal, and esophageal cancers, pose a significant global health burden. Despite advancements in diagnostic tools, early detection remains challenging, particularly in low-resource settings. Emerging evidence highlights the platelet-to-high-density lipoprotein ratio (PHR) as a novel biomarker integrating systemic inflammation and lipid metabolism. However, its association with GI cancer risk remains underexplored.

METHODS

This study utilized data from the National Health and Nutrition Examination Survey (NHANES) from 2010 to 2018, comprising 19,388 participants, including 230 with GI cancers. PHR was calculated as the ratio of platelet count to high-density lipoprotein cholesterol levels and categorized into quartiles. Weighted logistic regression models, restricted cubic spline analysis, and subgroup analyses were employed to evaluate the association between PHR and GI cancer risk, adjusting for demographic, socioeconomic, lifestyle, and clinical factors.

RESULTS

Elevated PHR was independently associated with an increased risk of GI cancers. Participants in the highest PHR quartile exhibited a significantly higher risk (adjusted OR = 3.09; 95% CI: 2.16-4.43) compared to the lowest quartile. A dose-response relationship was observed, with two critical inflection points at PHR values of 3.2 and 4.5. Subgroup analyses revealed stronger associations among older adults, males, and obese individuals. The findings suggest that PHR may reflect the dynamic balance of systemic inflammation and lipid metabolism, contributing to tumorigenesis.

CONCLUSION

This study identifies PHR as a promising, cost-effective biomarker for early detection and risk stratification of GI cancers. Its integration into screening programs could improve precision medicine strategies by identifying high-risk individuals for early intervention. Further longitudinal and mechanistic studies are warranted to confirm these findings and explore the underlying biological mechanisms.

摘要

背景

胃肠道癌症,包括胃癌、结直肠癌和食管癌,给全球健康带来了重大负担。尽管诊断工具有所进步,但早期检测仍然具有挑战性,尤其是在资源匮乏的地区。新出现的证据强调血小板与高密度脂蛋白比值(PHR)是一种整合全身炎症和脂质代谢的新型生物标志物。然而,其与胃肠道癌症风险的关联仍未得到充分研究。

方法

本研究利用了2010年至2018年美国国家健康与营养检查调查(NHANES)的数据,共有19388名参与者,其中包括230名胃肠道癌症患者。PHR计算为血小板计数与高密度脂蛋白胆固醇水平的比值,并分为四分位数。采用加权逻辑回归模型、受限立方样条分析和亚组分析来评估PHR与胃肠道癌症风险之间的关联,并对人口统计学、社会经济、生活方式和临床因素进行了调整。

结果

PHR升高与胃肠道癌症风险增加独立相关。与最低四分位数相比,PHR最高四分位数的参与者风险显著更高(调整后的OR = 3.09;95% CI:2.16 - 4.43)。观察到剂量反应关系,在PHR值为3.2和4.5时有两个关键拐点。亚组分析显示,在老年人、男性和肥胖个体中关联更强。研究结果表明,PHR可能反映了全身炎症和脂质代谢的动态平衡,有助于肿瘤发生。

结论

本研究确定PHR是一种有前景、具有成本效益的生物标志物,可用于胃肠道癌症的早期检测和风险分层。将其纳入筛查计划可以通过识别高危个体进行早期干预来改善精准医学策略。有必要进行进一步的纵向和机制研究以证实这些发现并探索潜在的生物学机制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f13/12036308/5292575219dd/12876_2025_3860_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验